CDK4 and bladder transitional cell carcinoma: Therapeutic interventions often exploit senescence: HSP90 inhibitor BIIB021 alters cancer-related genes, including those involved in senescence, to suppress BLCA growth [241], while CDK4/6 inhibitors such as palbociclib induce G1 arrest and senescence in RB + BLCA cells [242].